Methyl 3-hydroxy-2,5-dimethoxy-2-methyloxolane-3-carboxylate | 171963-06-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Methyl 3-hydroxy-2,5-dimethoxy-2-methyloxolane-3-carboxylate
• CAS: 171963-06-7
• 化学式: C₉H₁₆O₆
• 分子量: 220.222
• InChiKey: QISLDYCDVJHPSK-UHFFFAOYSA-N

物化性质

• 沸点：
  275.9±40.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Methyl 3-hydroxy-2,5-dimethoxy-2-methyloxolane-3-carboxylate 、 13-[(4-Methoxyphenyl)methyl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-12-one 在 camphor-10-sulfonic acid 作用下， 以 1,2-二氯乙烷 为溶剂， 以20%的产率得到methyl (15R,16S,18S)-16-hydroxy-4-[(4-methoxyphenyl)methyl]-15-methyl-5-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16-carboxylate
  参考文献：
  名称：

  The total synthesis of (±)K252a

  摘要：

  The total synthesis of (+/-)K252a (1) has been achieved following a convergent approach in which an acid-catalyzed bis-glycosidation reaction serves as a key step.

  DOI：

  10.1016/0040-4039(95)01811-u
• 作为产物：
  描述：

  甲醇 、 Methyl 2-hydroxy-3-oxo-2-(2-oxoethyl)butanoate 在 camphor-10-sulfonic acid 作用下， 生成 Methyl 3-hydroxy-2,5-dimethoxy-2-methyloxolane-3-carboxylate
  参考文献：
  名称：

  The total synthesis of (±)K252a

  摘要：

  The total synthesis of (+/-)K252a (1) has been achieved following a convergent approach in which an acid-catalyzed bis-glycosidation reaction serves as a key step.

  DOI：

  10.1016/0040-4039(95)01811-u

文献信息

• Compounds for immunopotentiation
  申请人：Valiante Nicholas

  公开号：US20100226931A1

  公开（公告）日：2010-09-09

  Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed. In a preferred embodiment benzopyrimidine derivatives such as ZD-6474, MLN-518, lapatinib, gefitinib or erlotinib are used.

  本发明公开了刺激免疫反应和治疗对3,4-二（1H-吲哚-3-基）-1H-吡咯-2,5-二酮，链霉菌素类似物，衍生的吡啶并嗪，香豆素-4-酮，吲哚酮，喹唑啉，核苷类似物和其他小分子具有响应性的患者。在一种优选实施方式中，使用苯并嘧啶衍生物，例如ZD-6474，MLN-518，拉帕替尼，吉非替尼或厄洛替尼。
• Syntheses of (−)-(7S)- and (+)-(7R)-K252a dimers
  作者：Kazuhiko Tamaki、Elliott W.D Huntsman、Dejah T Petsch、John L Wood

  DOI：10.1016/s0040-4039(01)02166-9

  日期：2002.1

  This letter describes syntheses of (-)-(7S)-and (+)-(7R)-K252a dimers wherein a convergent bis-indole-N-glycosidic coupling step was used for the resolution of the C(7) substituted (+/-)-aglycon. Dimerization of the derived monomers was achieved via olefin methathesis. (C) 2002 Elsevier Science Ltd. All rights reserved.
• The total synthesis of (±)K252a
  作者：Timothy B. Lowinger、Jingxi Chu、Patrick L. Spence

  DOI：10.1016/0040-4039(95)01811-u

  日期：1995.11

  The total synthesis of (+/-)K252a (1) has been achieved following a convergent approach in which an acid-catalyzed bis-glycosidation reaction serves as a key step.